Biodexa Pharmaceuticals Plc (BDRX) Stock Price & Analysis
Biodexa Pharmaceuticals Plc (BDRX) — MoonshotScore 29/100 (Weak band), calculated Oct 5, 2026. Price $0.6055 (-2.32%), as of the Oct 5, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Biodexa Pharmaceuticals Plc · BDRX
The company is currently advancing its drug candidates through clinical trials and offers advanced drug delivery platforms.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Biodexa Pharmaceuticals (BDRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Cheap, but weak quality, a fragile balance sheet and average growth, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Falling.
- EPS beat 2 of 5
- Altman Z -15.89 · Piotroski F 1
- ROE -55.8% · ROA -35.1% · current ratio 2.03
Holding back: weak fundamentals, balance-sheet strain, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
The score was 29 in the stored Oct 4, 2026 snapshot and remains 29 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.6055 | |
| Change on the day | -2.32% | |
| 52-week range | $0.5715 – $59.40 | |
| Shares traded on the day | 89.1K |
Price & events
Other perspectives
Council score for Biodexa Pharmaceuticals (BDRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BDRX film — every key number, told as a short cinematic story
~2 min · open the film
What is Biodexa Pharmaceuticals (BDRX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Biodexa Pharmaceuticals Plc (BDRX) is the company analyzed here. It employs 11 people and is led by Stephen Anthony Stamp.
What do the latest results show for Biodexa Pharmaceuticals (BDRX)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of 5 reports.
What are the financial strengths and risks for Biodexa Pharmaceuticals (BDRX)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -15.89 · Piotroski F 1. Trailing ratios: ROE -55.8% · ROA -35.1% · current ratio 2.03.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -15.89 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-55.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Biodexa Pharmaceuticals (BDRX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $5,687 · EPS -0.00 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for BDRX.
Checked against the records this page reads, on the dates shown above.
How does Biodexa Pharmaceuticals compare with its peers?
Short answer
Biodexa Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $503.50 Oct 5, 2026 | $128B | 97 5-pillar Oct 5, 2026 | |
| $726.94 Oct 5, 2026 | $75.7B | 94 5-pillar Oct 5, 2026 | |
| $7.26 Oct 5, 2026 | $571M | 94 5-pillar Oct 5, 2026 | |
| $10.70 Oct 5, 2026 | $591M | 91 5-pillar Oct 5, 2026 | |
| $4.55 Oct 5, 2026 | $669M | 88 5-pillar Oct 5, 2026 | |
| $140.93 Oct 5, 2026 | $267B | 84 5-pillar Oct 5, 2026 | |
| $16.90 Oct 5, 2026 | $90.6M | 83 5-pillar Oct 5, 2026 | |
| $9.75 Oct 5, 2026 | $88.2M | 77 5-pillar Oct 5, 2026 | |
| $4.55 Oct 5, 2026 | $184M | 76 5-pillar Oct 5, 2026 | |
| $2.71 Oct 5, 2026 | $218M | 73 5-pillar Oct 5, 2026 | |
| $2.68 Oct 5, 2026 | $222M | 68 5-pillar Oct 5, 2026 | |
| $11.05 Oct 5, 2026 | $640M | 68 5-pillar Oct 5, 2026 | |
| Biodexa Pharmaceuticals (BDRX) — this page | $0.6055 | — | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $5,687
- EPS estimate
- $-0.00
Measured against a quoted price of $0.6055 (as of Oct 5, 2026).
What has been published about Biodexa Pharmaceuticals (BDRX)?
Common Questions About BDRX
These answers are editorial: 1 of these 9 answers is drawn from the BDRX research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BDRX?
BDRX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BDRX a good stock to buy?
Stock Expert AI does not rate BDRX buy, sell or hold. Biodexa Pharmaceuticals Plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BDRX stock price today?
The last price recorded on this page for Biodexa Pharmaceuticals Plc (BDRX) is $0.6055, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for BDRX?
Biodexa Pharmaceuticals faces several risks, including the inherent uncertainty of clinical trial outcomes, which could significantly impact its growth trajectory.
What are the key factors to evaluate for BDRX?
Biodexa Pharmaceuticals Plc (BDRX) holds a MoonshotScore in the low range. Dividend Yield: None, as the company reinvests in R&D rather than returning capital to shareholders. Not financial advice.
How frequently does BDRX data refresh on this page?
BDRX's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BDRX's recent stock price performance?
Biodexa Pharmaceuticals Plc (BDRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug candidates addressing significant unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BDRX overvalued or undervalued right now?
Biodexa Pharmaceuticals Plc (BDRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BDRX before investing?
Before investing in Biodexa Pharmaceuticals Plc (BDRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 4 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.6055 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T17:24:41.911Z. | |
px.change | Change on the day | -2.32% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.0144 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 89.1K | FMP | Financial Modeling Prep (FMP) · quote |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 5 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-14 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -15.89 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -55.8% · ROA -35.1% · current ratio 2.03 | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $0.5715 – $59.40 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.employees | Employees | 11 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.ceo | Chief executive | Stephen Anthony Stamp | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $5,687 · EPS -0.00 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $5,687 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-0.00 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 29 of 100 · Weak · pillars 27 / 21 / 69 / 44 / 8 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 29 (stored snapshot Oct 4, 2026) → 29 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.